HK1250161B - 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 - Google Patents

6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途

Info

Publication number: HK1250161B
Authority: HK; Hong Kong
Prior art keywords: morpholinyl; pyrazolyl; purine derivatives; pi3k inhibitors; pi3k
Prior art date: 2015-03-30

Application number

HK18109578.1A

Other languages

English (en)

Inventor

Kirandeep Kaur Samby

Yogesh Baban Surase

Sagar Ramdas Amale

Suresh Kumar Gorla

Priyanka Patel

Ashwani Kumar Verma

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-30

Filing date

2018-07-24

Publication date

2020-05-15

2018-07-24 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2020-05-15 Publication of HK1250161B publication Critical patent/HK1250161B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

HK18109578.1A 2015-03-30 2018-07-24 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 HK1250161B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN878DE2015		2015-03-30
PCT/IB2016/051762 WO2016157074A1 (en)	2015-03-30	2016-03-29	6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number	Publication Date
HK1250161B true HK1250161B (zh)	2020-05-15

Family

ID=55854760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18109578.1A HK1250161B (zh)	2015-03-30	2018-07-24	6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途

Country Status (30)

Country	Link
US (1)	US10174035B2 (zh)
EP (1)	EP3277682B1 (zh)
JP (1)	JP6669417B2 (zh)
KR (1)	KR20170131444A (zh)
CN (1)	CN107428756B (zh)
AU (1)	AU2016242080B2 (zh)
BR (1)	BR112017020818A2 (zh)
CA (1)	CA2980517C (zh)
CO (1)	CO2017011020A2 (zh)
CY (1)	CY1122018T1 (zh)
DK (1)	DK3277682T3 (zh)
ES (1)	ES2733505T3 (zh)
HK (1)	HK1250161B (zh)
HR (1)	HRP20190998T1 (zh)
HU (1)	HUE045192T2 (zh)
IL (1)	IL254688B (zh)
LT (1)	LT3277682T (zh)
MX (1)	MX2017012390A (zh)
MY (1)	MY185268A (zh)
PH (1)	PH12017501750A1 (zh)
PL (1)	PL3277682T3 (zh)
PT (1)	PT3277682T (zh)
RS (1)	RS59213B1 (zh)
RU (1)	RU2710549C2 (zh)
SG (1)	SG11201706509QA (zh)
SI (1)	SI3277682T1 (zh)
TR (1)	TR201910941T4 (zh)
TW (1)	TWI689508B (zh)
WO (1)	WO2016157074A1 (zh)
ZA (1)	ZA201705530B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201817731A (zh) *	2016-09-29	2018-05-16	日商第一三共股份有限公司	［２－（１－甲基－１ｈ－吡唑－４－基）－６－（啉－４－基）－９ｈ－嘌呤－８－基］［４－（啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶
CN107163061A (zh) *	2017-04-14	2017-09-15	江西科技师范大学	含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
CN110963955A (zh) *	2018-09-30	2020-04-07	南京富润凯德生物医药有限公司	一种单氟代螺环化合物的合成方法及其中间体
CN111087336A (zh) *	2018-10-24	2020-05-01	南京富润凯德生物医药有限公司	一种双氟代螺环化合物的合成方法及其中间体
CN110577515B (zh) *	2019-09-02	2022-05-17	南通大学	一种4-(氮杂环丁烷-3-基)-1-甲基哌嗪-2-酮二盐酸盐的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7122665B2 (en)	2002-10-15	2006-10-17	Synta Pharmaceuticals Corp.	Heterocyclic compounds
AU2004251641A1 (en)	2003-05-29	2005-01-06	Synta Pharmaceuticals, Corp	Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB2431156A (en)	2005-10-11	2007-04-18	Piramed Ltd	1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
KR101422301B1 (ko) *	2006-04-26	2014-07-30	에프. 호프만-라 로슈 아게	약학적 화합물
TW200801012A (en) *	2006-04-26	2008-01-01	Piramed Ltd	Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20080233127A1 (en)	2007-03-21	2008-09-25	Wyeth	Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2009034386A1 (en)	2007-09-13	2009-03-19	Astrazeneca Ab	Derivatives of adenine and 8-aza-adenine and uses thereof-796
US20110009403A1 (en)	2007-10-05	2011-01-13	S*Bio Pte Ltd.	2-morpholinylpurines as inhibitors of pi3k
CN101889015B (zh)	2007-10-05	2014-06-04	维拉斯通股份有限公司	嘧啶取代的嘌呤衍生物
ES2537624T3 (es)	2007-10-26	2015-06-10	F. Hoffmann-La Roche Ag	Derivados purina útiles como inhibidores de la quinasa PI3
EP2244709A4 (en)	2008-02-07	2012-02-29	Synta Pharmaceuticals Corp	TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
EP2279188B1 (en)	2008-05-30	2015-01-28	Genentech, Inc.	Purine pi3k inhibitor compounds and methods of use
US8513221B2 (en)	2008-07-07	2013-08-20	Xcovery Holding, LLC	PI3K isoform selective inhibitors
TWI378933B (en)	2008-10-14	2012-12-11	Daiichi Sankyo Co Ltd	Morpholinopurine derivatives
WO2010114494A1 (en)	2009-04-03	2010-10-07	S*Bio Pte Ltd	8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
CA2772371A1 (en)	2009-05-27	2010-12-02	F. Hoffmann-La Roche Ag	Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2761445A1 (en) *	2009-05-27	2010-12-02	Genentech, Inc.	Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
ES2596654T3 (es)	2009-11-12	2017-01-11	F. Hoffmann-La Roche Ag	Compuestos de purina N-9-sustituida, composiciones y métodos de uso
CA2802808A1 (en)	2010-07-14	2012-01-19	F. Hoffmann-La Roche Ag	Purine compounds selective for pi3k p110 delta, and methods of use
US9346807B2 (en)	2010-09-14	2016-05-24	Exelixis, Inc.	Inhibitors of PI3K-delta and methods of their use and manufacture
KR101548439B1 (ko)	2010-12-16	2015-08-28	에프. 호프만-라 로슈 아게	트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
ES2611885T3 (es)	2011-01-31	2017-05-11	Novartis Ag	Derivados heterocíclicos novedosos
EP2673269A1 (en)	2011-02-09	2013-12-18	F.Hoffmann-La Roche Ag	Heterocyclic compounds as pi3 kinase inhibitors

2016
- 2016-03-29 DK DK16718910.9T patent/DK3277682T3/da active
- 2016-03-29 LT LTEP16718910.9T patent/LT3277682T/lt unknown
- 2016-03-29 MX MX2017012390A patent/MX2017012390A/es active IP Right Grant
- 2016-03-29 CA CA2980517A patent/CA2980517C/en not_active Expired - Fee Related
- 2016-03-29 BR BR112017020818-0A patent/BR112017020818A2/pt not_active IP Right Cessation
- 2016-03-29 ES ES16718910T patent/ES2733505T3/es active Active
- 2016-03-29 CN CN201680019892.7A patent/CN107428756B/zh not_active Expired - Fee Related
- 2016-03-29 WO PCT/IB2016/051762 patent/WO2016157074A1/en active Application Filing
- 2016-03-29 TR TR2019/10941T patent/TR201910941T4/tr unknown
- 2016-03-29 JP JP2017545934A patent/JP6669417B2/ja active Active
- 2016-03-29 SI SI201630267T patent/SI3277682T1/sl unknown
- 2016-03-29 KR KR1020177026959A patent/KR20170131444A/ko not_active Application Discontinuation
- 2016-03-29 PT PT16718910T patent/PT3277682T/pt unknown
- 2016-03-29 MY MYPI2017001151A patent/MY185268A/en unknown
- 2016-03-29 SG SG11201706509QA patent/SG11201706509QA/en unknown
- 2016-03-29 EP EP16718910.9A patent/EP3277682B1/en active Active
- 2016-03-29 TW TW105109845A patent/TWI689508B/zh not_active IP Right Cessation
- 2016-03-29 AU AU2016242080A patent/AU2016242080B2/en not_active Ceased
- 2016-03-29 RU RU2017134110A patent/RU2710549C2/ru active
- 2016-03-29 US US15/560,466 patent/US10174035B2/en active Active
- 2016-03-29 PL PL16718910T patent/PL3277682T3/pl unknown
- 2016-03-29 RS RSP20190941 patent/RS59213B1/sr unknown
- 2016-03-29 HU HUE16718910A patent/HUE045192T2/hu unknown
2017
- 2017-08-15 ZA ZA2017/05530A patent/ZA201705530B/en unknown
- 2017-09-25 IL IL254688A patent/IL254688B/en active IP Right Grant
- 2017-09-25 PH PH12017501750A patent/PH12017501750A1/en unknown
- 2017-10-27 CO CONC2017/0011020A patent/CO2017011020A2/es unknown
2018
- 2018-07-24 HK HK18109578.1A patent/HK1250161B/zh not_active IP Right Cessation
2019
- 2019-06-03 HR HRP20190998TT patent/HRP20190998T1/hr unknown
- 2019-07-19 CY CY20191100773T patent/CY1122018T1/el unknown

Also Published As

Publication number	Publication date
JP6669417B2 (ja)	2020-03-18
AU2016242080A1 (en)	2017-08-24
CY1122018T1 (el)	2020-10-14
EP3277682B1 (en)	2019-04-24
TW201643162A (zh)	2016-12-16
DK3277682T3 (da)	2019-07-29
SI3277682T1 (sl)	2019-06-28
IL254688B (en)	2021-03-25
CN107428756A (zh)	2017-12-01
US10174035B2 (en)	2019-01-08
CA2980517C (en)	2020-02-25
EP3277682A1 (en)	2018-02-07
ZA201705530B (en)	2018-05-30
PT3277682T (pt)	2019-07-09
MX2017012390A (es)	2018-01-26
TR201910941T4 (tr)	2019-08-21
RS59213B1 (sr)	2019-10-31
BR112017020818A2 (pt)	2018-07-03
MY185268A (en)	2021-04-30
WO2016157074A1 (en)	2016-10-06
RU2017134110A (ru)	2019-04-03
SG11201706509QA (en)	2017-09-28
RU2017134110A3 (zh)	2019-06-11
PH12017501750A1 (en)	2018-04-02
IL254688A0 (en)	2017-11-30
PL3277682T3 (pl)	2019-09-30
RU2710549C2 (ru)	2019-12-27
CA2980517A1 (en)	2016-10-06
HRP20190998T1 (hr)	2019-10-18
TWI689508B (zh)	2020-04-01
JP2018510146A (ja)	2018-04-12
LT3277682T (lt)	2019-06-25
KR20170131444A (ko)	2017-11-29
CN107428756B (zh)	2019-07-23
US20180072732A1 (en)	2018-03-15
HUE045192T2 (hu)	2019-12-30
CO2017011020A2 (es)	2018-01-16
AU2016242080B2 (en)	2019-09-19
ES2733505T3 (es)	2019-11-29

Publication	Publication Date	Title
IL278916A (en)	2021-01-31	Benzoimidazole derivatives as PAD4 inhibitors
IL258081B (en)	2022-10-01	Benzimidazole history and their use
HK1248520A1 (zh)	2018-10-19	Egfr和pi3k的小分子抑制劑
IL254318B (en)	2019-08-29	History of benzaimidazoles as bromodomain inhibitors
AP2016009487A0 (en)	2016-10-31	Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
AP2015008783A0 (en)	2015-10-31	6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
HK1232227A1 (zh)	2018-01-05	作為抑制劑的喹嗪酮衍生物
HK1250161B (zh)	2020-05-15	6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
HK1250926A1 (zh)	2019-01-18	抑制劑及其應用
HK1250028A1 (zh)	2018-11-23	2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
IL261645A (en)	2018-10-31	History of dioxo-hexahydroisoindolyl and their use as cyclophilin inhibitors
PL3362450T3 (pl)	2021-08-23	N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej
IL258690A (en)	2018-06-28	Pyridone derivatives and their use as kinase inhibitors
SI3224253T1 (sl)	2020-02-28	Derivati bis(sulfonamida) in njihova uporaba kot zaviralci MPGES
GB201505971D0 (en)	2015-05-20	Inhibitors and their uses
GB201505975D0 (en)	2015-05-20	Inhibitors and their uses
GB201509381D0 (en)	2015-07-15	Novel compounds and their use as kinase inhibitors
GB201505460D0 (en)	2015-05-13	Novel compounds and their use as kinase inhibitors
GB201409661D0 (en)	2014-07-16	Novel compounds and their use as kinase inhibitors
GB201405532D0 (en)	2014-05-14	Novel compounds and their use as Kinase inhibitors

Legal Events

Date	Code	Title	Description
2024-10-25	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20240328